In Stock Cell Lines
Homo sapiens (Human)
Lung
Adherent
The DCC Knockout BEAS-2B Cell Line is a CRISPR/Cas9-edited knockout cell line in the BEAS-2B human bronchial epithelial background, disrupting the dependence receptor DCC. DCC binds Netrin-1 to mediate survival and axon guidance, while unleashing caspase-dependent apoptosis through UNC5 co-receptors and DAPK in its absence. This model enables study of DCC's tumor suppressor and apoptotic functions in non-tumorigenic lung epithelium. It is ideal for cancer research, apoptosis signaling, drug screening, and axon guidance studies. Assays such as Western blotting, caspase activity, migration, and netrin-1 treatment can dissect DCC-dependent pathways in airway cells. Contact Ascent Research for ordering.
LETMD1 Knockout HT29 Polyclonal Cells
Cat. No. ARG15023
MVK Knockout Hela Polyclonal Cells
Cat. No. ARG8966
ACSF2 Knockout NCI-H1299 Polyclonal Cells
Cat. No. ARG30220
EPHA1 Knockout HCT116 Polyclonal Cells
Cat. No. ARG7067
NR3C1 Knockout MES-OV Polyclonal Cells
Cat. No. ARG6556
Mouse Pulmonary Artery Smooth Muscle Cell Medium
Cat. No. ARM0429
The DCC Knockout BEAS-2B Cell Line is a CRISPR/Cas9-edited knockout cell line derived from BEAS-2B human bronchial epithelial cells, featuring disruption of the DCC gene. This loss-of-function model enables investigation of DCC-dependent signaling pathways in a non-tumorigenic lung epithelial context. By eliminating DCC expression, researchers can dissect its roles as a dependence receptor and tumor suppressor without confounding transformation-associated alterations.
BEAS-2B cells are an SV40-immortalized, non-tumorigenic human bronchial epithelial cell line that retains key characteristics of normal airway epithelium, including barrier function and polarized morphology. Widely employed in respiratory biology, these cells provide a physiologically relevant platform for studying epithelial integrity, migration, and responses to extracellular cues. Their non-transformed status makes them particularly suitable for examining mechanisms of apoptosis and tumor suppression.
DCC encodes a transmembrane receptor for Netrin-1, classified as a dependence receptor: upon ligand binding, it mediates axon guidance and pro-survival signals, whereas in the absence of Netrin-1, DCC triggers a caspase-dependent apoptotic pathway. Mechanistically, unbound DCC recruits and activates caspase-9 and caspase-3, often in concert with DAPK, to form a death-inducing signaling complex. DCC also interacts with UNC5A, UNC5B, and UNC5C co-receptors, which can modulate apoptotic sensitivity, and engages adaptor proteins such as APPL1 and DIP13??. Context-dependent ERK1/2 signaling further diversifies its downstream outputs. This dichotomous functionality positions DCC as a critical tumor suppressor, with loss of expression or function observed in colorectal, gastric, and neuroblastoma malignancies, as well as congenital mirror movement disorders.
In the BEAS-2B bronchial epithelial background, DCC knockout provides a powerful tool to explore how loss of this dependence receptor impacts lung epithelial homeostasis. The non-tumorigenic nature of the host cells allows clean dissection of DCC’s apoptotic and migratory functions without interference from oncogenic mutations. Researchers can assess the effect of DCC disruption on barrier integrity, netrin-1-mediated survival, and caspase activation under physiologically relevant conditions, shedding light on early steps in respiratory carcinogenesis.
This knockout cell line supports a broad range of research applications, including cancer biology, apoptosis signaling, axon guidance, and tumor suppression studies. It is well-suited for functional assays such as Western blotting, caspase activity measurements, netrin-1 treatment experiments, migration assays, and immunofluorescence. Transcriptomic analyses (RNA-seq, RT-qPCR) and barrier integrity assays can further elucidate DCC-dependent gene networks. The line also enables drug screening for compounds targeting the Netrin-1/DCC interaction in lung and other cancers. For additional information, please contact Ascent Research.